RUNX3 is silenced by histone modification and hypoxia-inducible factor (HIF)-1a is stabilized under hypoxia, but little is known of cross-talk between RUNX3 and HIF-1a under hypoxia. In the present study, the authors investigated the effect of RUNX3 on HIF-1a stability in gastric cancer cells. RUNX3 overexpression was found to downregulate HIF-1a stability under normoxic and hypoxic conditions. Furthermore, the activity of a luciferase reporter containing five copies of vascular endothelial growth factor (VEGF) promoter hypoxia-responsive element (5 Â HRE) and the amount of secreted VEGF, were diminished in RUNX3-expressing but increased in RUNX3-knockdown cells. When expression of RUNX3 was recovered using epigenetic reagents the expressions of HIF-1a and VEGF were clearly suppressed under hypoxic conditions. RUNX3 also significantly attenuated the half-life of HIF-1a protein, and induced the cytosolic localization and ubiquitination of HIF-1a. In addition, RUNX3 directly interacted with the C-terminal activation domain of HIF-1a and prolyl hydroxylase (PHD) 2 and enhanced the interaction between HIF-1a and PHD2, which potentiated proline hydroxylation and promoted the degradation of HIF-1a. Furthermore, RUNX3 overexpression significantly inhibited hypoxia-induced angiogenesis in vitro and in vivo. Taken together, these results suggest that RUNX3 destabilizes HIF-1a protein by promoting the proline hydroxylation of HIF-1a through binding to HIF-1a/PHD2. RUNX3 appears to be a novel suppressor of HIF-1a and of hypoxia-mediated angiogenesis in gastric cancer cells.
INTRODUCTION
In solid tumors larger than 1 mm 3 , tumor cells removed from blood vessels experience hypoxia. 1, 2 Furthermore, hypoxia stabilizes hypoxia-inducible factor (HIF)-1a, which dimerizes with aryl hydrocarbon receptor nuclear translocator or HIF-1b, a constitutively expressed binding partner of several bHLH-PAS domain proteins, to increase the HIF-1-mediated gene transcriptions involved in tumor angiogenesis, survival, apoptosis and glycolysis. 3 Of the numerous angiogenic factors discovered to date, vascular endothelial growth factor (VEGF) has been shown to be a key mediator of tumor angiogenesis and to be primarily regulated by hypoxia and HIF-1. 3 Like other solid tumors, the growth and metastasis of gastric cancer depend on angiogenesis, that is, the formation of new blood vessels from a pre-existing network of capillaries. 4 Furthermore, elevated VEGF expression in human tumor biopsy specimens has been reported in various cancers, including gastric cancer, and shown to be significantly correlated with tumor angiogenesis and metastatic potential. 5 Under normoxic conditions, HIF-1a is rapidly degraded by the ubiquitin-proteasome pathway, 6 and its ubiquitination is mediated by an interaction between HIF-1a and the tumor suppressor pVHL (von Hippel-Lindau protein). 7 This process is triggered by the post-translational hydroxylation of specific proline residues mediated by prolyl hydroxylases (PHDs) or HIF prolyl hydroxylase. Proline hydroxylation at P402 and P564 of the oxygen-dependent degradation (ODD) domain region of HIF-1a 8 recruits pVHL E3-ubiquitin-protein ligase complex, and thus, targets HIF-1a for destruction. 9 RUNX3 is a runt-domain transcription factor, and functions as a tumor suppressor in gastric cancer. In fact, RUNX3 À / À mouse gastric mucosa exhibits hyperplasia due to stimulated proliferation and the suppression of apoptosis. 10 RUNX3 is frequently silenced in solid tumors, including those of gastric cancer, by hemizygous deletion and DNA promoter hypermethylation. 10, 11 In fact, RUNX3 silencing indicates a poor clinical prognosis in gastric cancer, and thus, is believed to be related to tumor progression and metastasis. [12] [13] [14] Recently, we reported the silencing of RUNX3 under hypoxic conditions and that this silencing was mediated by the induction of histone methylation and the deacetylation of RUNX3 promoter by G9a histone methyl transferase and histone deacetylase 1 (HDAC1). 1 Furthermore, we suspect that this decreased expression of RUNX3 under hypoxia might potentiate tumor progression in gastric cancer by aggravating the angiogenic microenvironment. However, the roles played by RUNX3 in HIF-1a stability and angiogenesis under hypoxic conditions are largely unknown.
In the present study, we utilized RUNX3-expressing and nonexpressing gastric cancer cells and compared the expressions of HIF-1a and its downstream targeted gene, VEGF, under normoxic and hypoxic conditions. We found that RUNX3 inhibits HIF-1a stability, HIF-1a-dependent angiogenesis and tumor progression under hypoxic conditions. RESULTS RUNX3 attenuated the expressions of HIF-1a protein and VEGF mRNA in hypoxia To investigate the role of RUNX3 in angiogenesis under hypoxic conditions, we transfected HEK293 embryonic kidney epithelial cells and SNU668 RUNX3-silenced gastric cancer cells, which both express low levels of RUNX3, with full-length RUNX3 expression plasmid. RUNX3 overexpression significantly reduced HIF-1a protein and VEGF, carbonic anhydrase 9, glucose transporter 1, aldolase C and phosphoglycerate kinase mRNA levels in both cell lines under hypoxic conditions not under normoxic conditions (Figure 1a ). When we checked mRNA expression in SNU668 cells after forcing RUNX3 overexpression, HIF-1a mRNA levels were not changed by RUNX3. This result suggests that RUNX3 does not regulate HIF-1a at the transcription level (Figure 1a) . In a previous study, hypoxia decreased RUNX3 expression in MKN1 and MKN45 gastric cancer cells, which express high levels of RUNX3. 1 In the present study, RUNX3 overexpression under hypoxic conditions decreased HIF-1a protein, VEGF, carbonic anhydrase 9, glucose transporter 1, aldolase C and phosphoglycerate kinase mRNA levels in MKN1 cells (Figure 1b) . Because HIF-1a protein was not detected under normoxic conditions in MKN1 cells, we investigated the effect of RUNX3 on the protein level of HIF-1a under hypoxic conditions (Figure 1b ). Desferrioxamine (a hypoxia mimic) also increased HIF-1a stability in HEK293 cells, but RUNX3 decreased the desferrioxamine-induced expressions of HIF-1a Figure 1 . HIF-1a protein and HIF-1 target gene expression by RUNX3 overexpression. HEK293, SNU668 MKN1 and MKN45 cells were transfected with mock or RUNX3 full-length plasmid and exposed to normoxic (N) or hypoxic (H) conditions for 24 h. (a) HEK293 (expressing low RUNX3 levels) and SNU668 cells (not expressing RUNX3) were transfected with RUNX3 full-length plasmid and exposed to hypoxia for 24 h. (b) RUNX3-expressing MKN1 and MKN45 gastric cancer cells were transfected with each vector and exposed to hypoxic (H) conditions for 24 h. (c) HEK293 cells were transfected with each vector and then treated with desferrioxamine (160 mM) for 24 h. Alpha-tubulin and b-actin was used as internal controls for western blotting and -real-time PCR, respectively. Relative protein expression levels (plotted below the band pictures) were quantified using ImageJ (NIH, Bethesda, MO, USA) and normalized versus internal controls. Three independent experiments were performed and representative results are shown.
protein and VEGF mRNA (Figure 1c) . These results suggest that RUNX3 decreases HIF-1a stability and further inhibits the expression of angiogenic molecules, such as, VEGF.
Restoration of RUNX3 by epigenetic regulating agents under hypoxia decreased the expressions of HIF-1a and VEGF We confirmed hypoxia-silenced RUNX3 by histone modification and that this silencing was recovered by 5-aza-2-deoxycytidine (5-Aza, an inhibitor of DNA methyltransferase (or histone methyl transferase)) and by trichostatin A (TSA, an HDAC inhibitor) 1 ( Figure 2a) . Treatments with 5-Aza or TSA reduced the levels of HIF-1a and VEGF proteins under hypoxic conditions in MKN45 cells, but HIF-1a mRNA levels were unchanged (Figure 2b ), which suggested RUNX3 regulates HIF-1a stability at the post-translational level and that RUNX3 silencing under hypoxic conditions can result in tumor angiogenesis via HIF-1. Because treatment of 5-Aza or TSA can modulate gene and protein expression levels globally, TSA had a stronger effect on HIF-1a levels and VEGF secretion than 5-Aza, although RUNX3 expression was equally recovered by these reagents. In this experiment, we only focused on RUNX3 recovering ability and tested these chemicals for RUNX3-HIF-VEGF axis. Further, examination of conditioned media (CM) from MKN45 gastric cancer cells treated with 5-Aza or TSA confirmed that both the agents inhibited the secretion of VEGF protein under hypoxic conditions (Figure 2c ).
RUNX3 attenuated VEGF secretion and promoter activity To expand the semiquantitative real-time PCR finding regarding HIF-1-mediated gene transcription and to exclude the direct regulation of VEGF by RUNX3, 15 we performed a luciferase reporter assay using a pGL3 luciferase plasmid containing only 5 Â HRE (hypoxia-responsive element) of VEGF promoter but not containing its RUNX3 binding sites. 16 Luciferase activity was increased by hypoxic stress in RUNX3-expressing MKN1 cells, but RUNX3 overexpression decreased VEGF reporter activity (Figure 3a) . In RUNX3-silenced SNU668 cells under normoxic conditions, forced RUNX3 expression suppressed reporter activity, as was observed under hypoxic conditions (Figure 3a ). This result shows that RUNX3 downregulates VEGF promoter activity in a HIF-1-mediated manner under hypoxia.
When we quantified secreted VEGF levels under the same experimental conditions by enzyme-linked immunosorbent assay analysis of CM, RUNX3 overexpression in SNU668 and MKN1 cells was found to significantly inhibit the secretion of VEGF as compared with that observed in mock-transfectants (Figure 3b) . Interestingly, we observed that basal VEGF reporter activity and secreted VEGF levels were higher in SNU668 than in MKN1 cells. These results suggest RUNX3 silencing is a critical requirement for angiogenesis and that the restoration of RUNX3 prevented HIF-1-mediated angiogenesis in gastric cancer cells under hypoxic conditions. RUNX3 destabilized HIF-1a and increased HIF-1a ubiquitination HIF-1a is stabilized under hypoxic conditions, but is rapidly degraded under normoxic conditions by ubiquitination via E3-ubiquitin ligase pVHL. 6 Accordingly, we investigated whether RUNX3 regulates HIF-1a stability. HIF-1a protein levels were found to decrease with time after treatment with cycloheximide (a global inhibitor of protein synthesis). In the absence of RUNX3, the halflife of HIF-1a protein was 10.1 min, whereas in its presence its half-life was 3.5 min (Figure 4a ), suggesting that RUNX3 stimulates the degradation of HIF-1a. Under hypoxic conditions, RUNX3 was not expressed and endogenous HIF-1a was localized to the nucleus, but when RUNX3 was overexpressed, it was localized to the nucleus, in which HIF-1a was not expressed in MKN1 cells ( Figure 4b ). Next, we introduced the RUNX3 gene into HEK293 cells under hypoxic conditions and measured HIF-1a expressions. It was found that RUNX3 dose dependently decreased HIF-1a protein levels ( Figure 4c ). Furthermore, when HIF-1a degradation was blocked by MG132 (a proteasome inhibitor), RUNX3-mediated HIF-1a degradation was recovered ( Figure 4d ). In addition, in the presence of MG132, RUNX3 overexpression increased HIF-1a ubiquitination to the extent observed under normoxic conditions, whereas HIF-1a ubiquitination was clearly less under hypoxic conditions ( Figure 4e ). These results suggest that RUNX3 destabilizes HIF-1aby upregulating an ubiquitin-mediated protein degradation pathway.
RUNX3 directly interacted with HIF-1a CTAD and PHDs Next, we investigated whether RUNX3 interacts with HIF-1a after transfecting HEK293 cells with myc-tagged RUNX3 or green fluorescent protein-HIF-1a. Immunoprecipitation and western blotting data suggested that RUNX3 interacted with HIF-1a in vitro (Figure 5a ). Accordingly, we investigated whether endogenous RUNX3 interacts with HIF-1a under hypoxic conditions and sought to determine the time-line of this interaction. In MKN1 cells, RUNX3 was found to interact with HIF-1a after 1 h of hypoxia and maximally after 4-8 h of hypoxia ( Figure 5b ). Furthermore, HIF-1a levels peaked after 24 h of hypoxia, and the interaction between RUNX3 and HIF-1a was sustained after 24 h (Figure 5b ). We immunoprecipitated and western blotted MKN1 cells transfected with 3Myc-RUNX3, full-length or deletion mutants of glutathione-S-transferase-HIF-1a including a C-terminal and VEGF mRNA were checked by semiquantitative real-time PCR, whereas protein levels were determined by western blotting. Alphatubulin and b-actin were used as internal controls. Relative expression levels were quantified using ImageJ (NIH, Bethesda, MO, USA), and were normalized versus a-tubulin or b-actin and indicated by 'Fold' below the band pictures. Three independent experiments were performed and representative results are shown. (c) MKN45 cells were treated with 100 mM 5-Aza (A) and/or 300 nM TSA (T) under hypoxic conditions (H) for 24 h in serum-reduced culture media. Media supernatants were collected and secreted VEGF levels were determined ELISA after removing cell debris. Significant divergences from normoxia (N) were accepted for *P-values of o0.01 and from hypoxia for **P-values of o0.01. Three independent experiments were performed in triplicate. . Transfected cells were then exposed to normoxic (N) or hypoxic (H) conditions. Five copies of HRE promoter activities and relative luciferase activities were determined after normalizing with respect to b-galactosidase activity. (b) MKN1 and SNU668 cells were transfected with RUNX3 full-length plasmid ( þ R3) and cultured in serum-reduced culture media. Transfected cells were exposed to normoxic (N) or hypoxic (H) conditions for 24 h. Media supernatants were collected and secreted VEGF levels were determined by ELISA after removing cell debris. Significant differences from normoxia (N) were accepted for *P-values of o0.01 and from hypoxia for **P-values of o0.01. (a) MKN1 cells were transfected with mock or 3Myc-RUNX3 fulllength plasmid and exposed to hypoxic conditions for 24 h. Cells were then immediately treated with cycloheximide (CHX, 100 mM) for the indicated times and HIF-1a protein levels were determined by western blotting. b-actin was used as the internal control. The relative expression levels of control and RUNX3-overexpressing cells were plotted, and the half-life (t 1/2 ) of HIF-1a protein was determined. (b) MKN1 cells were transfected with pCS4-3Myc-RUNX3 full-length plasmid and exposed to hypoxia for 24 h. The expressions of RUNX3 and endogenous HIF-1a were determined using appropriate antibodies and FITC-and Texas-red labeled secondary antibodies. Nuclei were stained with DAPI. (c) HEK293 cells were transfected with different doses of 3Myc-RUNX3 full-length plasmid and exposed to hypoxic conditions for 24 h. RUNX3 and endogenous HIF-1a protein levels were determined by western blotting. (d) HEK293 cells were transfected with 3Myc-RUNX3 full-length plasmid under hypoxic conditions for 24 h with or without MG132 (100 mM, 6 h). RUNX3 and endogenous HIF-1a protein levels were determined by western blotting. (e) HEK293 cells were transfected with 3Myc-RUNX3 full-length plasmid, and 18 h later, cells were treated with MG132 (100 mM) for 6 h and cell lysates were immunoprecipitated with anti-HIF-1a antibody. Immunoprecipitates were immunoblotted using anti-ubiquitin antibody. Three independent experiments were performed and representative results are shown. transactivation domain (CTAD), an ODD domain and an NTAD containing amino acids 1-401. As shown in (Figure 5c ), RUNX3 was found to interact with the CTAD of HIF-1a. To identify the RUNX3 domains responsible for the stabilization of HIF-1a, we prepared deletion mutants of RUNX3. As shown in (Figure 5d ), the deletion mutants 325 and 187 had deletions starting at amino acids 325 and 187, respectively, whereas the entire runt-homology domain was deleted in the DRunt mutant. HIF-1a expression levels were lower in the wild-type 325 and DRunt mutants than in hypoxia alone, but not in 187 mutants, which suggested the N-terminal region containing the Runt-homology domain (1-187) is responsible for the stabilization of HIF-1a, and that the activation domain of RUNX3 is necessary for its destabilization. These results suggest that RUNX3 interacts directly with the C-terminal transactivation domain of HIF-1a to decrease its stability and that 1-187 RUNX3 is necessary for the stabilization of HIF-1a.
RUNX3 induced the prolyl hydroxylation of HIF-1a via PHDs HIF-1a is degraded by the ubiquitination-proteasome degradation system, for which the hydroxylation of proline residues (P402, P564) in the ODD domain of HIF-1a is a prerequisite. 5, 7 To determine whether RUNX3 regulates HIF-1a degradation via hydroxylation, we used the 2-oxoglutarate inhibitor dimethyloxallyl glycine, which impairs the activities of PHDs 17, 18 and leads to the inhibition of HIF-1a hydroxylation. As compared with normoxic conditions, hypoxia or dimethyloxallyl glycine, inhibited HIF-1a proline hydroxylation in MKN1 cells, but RUNX3 increased this hydroxylation and decreased HIF-1a levels. Furthermore, in the presence of dimethyloxallyl glycine, the increased hydroxylation by RUNX3 was suppressed (Figure 6a ). RUNX3 was found to inhibit HIF-1a expression, but had no effect on the alanine mutants of HIF-1a at 402 (P402A) and/or 564 (P564A) (Figure 6b ), indicating that hydroxylation of HIF-1a is a prerequisite for RUNX3-mediated HIF-1a degradation. Moreover, in the presence of these HIF-1a ODD mutants, VEGF levels were unaffected by RUNX3 (Figure 6c ), suggesting that RUNX3-mediated HIF-1a inhibition is essential for VEGF expression. PHD3 was not detected and no substantial changes in the expressions of the mRNAs of PHD1 and 2 were observed in RUNX3-overexpressing MKN1 cells (Figure 6d ). Thus, we checked the interaction between RUNX3 and PHD1/2. It was found that RUNX3 interacted with PHD1 and 2, but more strongly with PHD2 (Figure 6e ). Even green fluorescent-fused proteins are relatively stable because the half-life of green fluorescent protein is longer than that of other proteins, the regulation mechanism of green fluorescent protein-HIF-1a protein via PHDs and pVHL pathways has been shown to be the same as that of endogenous HIF-1a.
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Next, we examined the possibility that RUNX3 promotes the PHD2-mediated hydroxylation of HIF-1a. PHD2 was found to induce the degradation of HIF-1a dose dependently and this was potentiated by RUNX3 (Figure 6f ). These results suggest that RUNX3 destabilizes HIF-1a protein by stimulating its ubiquitination through proline hydroxylation by acting as an intermediary between PHD2 with HIF-1a at CTAD. We then checked whether RUNX3 regulates affinity between HIF-1a and PHD2. RUNX3 increased the interaction between HIF-1a and PHD2 (Figure 6g 
RUNX3 inhibited hypoxia-induced angiogenesis in vitro and in vivo
We further examined the role played by RUNX3 during the inhibition of angiogenesis under hypoxic conditions. As shown in (Figure 7a ), human umbilical vein endothelial cell proliferation was increased by hypoxia but CM from RUNX3-overexpressing cells significantly decreased this proliferation. Similarly, endothelial cell migration was stimulated by CM from hypoxic MKN1 cells, whereas the overexpression of RUNX3 under hypoxic conditions clearly diminished human umbilical vein endothelial cell migration (Figure 7b ). These results indicate that RUNX3 acts as an angiogenic inhibitory molecule under hypoxic conditions by inhibiting the proliferation, migration and maturation of vascular endothelial cells. To confirm this, we performed in vivo angiogenic assays using chick chorioallantoic membranes (CAM). CM obtained from RUNX3-overexpressing MKN1 cells under hypoxia was found to decrease neo-vessel formation significantly more than hypoxic CM (Figure 7c ). For a mouse Matrigel plug assay, we mixed growth factor-reduced Matrigel with cells expressing RUNX3 at moderate or low levels, and inoculated these into mouse flanks. In addition, we compared the angiogenic abilities of CMs from normoxic, hypoxic and RUNX3-overexpressing hypoxic MKN1 cells. As shown Figure 6 . RUNX3 destabilized HIF-1a by inducing the PHD2-mediated hydroxylation of HIF-1a. (a) MKN1 cells were transfected with pCS4-3Myc-RUNX3 full-length plasmid and exposed to hypoxia in the presence or absence of dimethyloxallyl glycine (20 mM). The expressions of HIF-1a and of hydroxylated (OH)-HIF-1a at P402 or P564 were determined using specific antibodies by western blotting. (b) HEK293 cells were transfected with HIF-1a wild-type (WT) and P402A/P564A point mutants in the presence or absence of RUNX3 plasmid. HIF-1a protein levels were determined by western blotting. b-Actin was used as the internal control. (c) VEGF protein levels were determined by western blotting using the same cell lysate with (b) as indicated. (d) MKN1 cells were transfected with pCS4-3Myc-RUNX3 full-length plasmid and exposed to hypoxic conditions. PHD1-3 mRNA levels were analyzed by real-time PCR. b-Actin was used as the internal control. (e) HEK293 cells were transfected with pEGFP-PHD1, -PHD2 and/or pCS4-3HA-RUNX3 plasmids. Whole-cell lysates were immunoprecipitated with an anti-GFP antibody and then probed with an anti-HA antibody. (f ) HEK293 cells were transfected with pEGFP-HIF-1a, -PHD2 and/or pCS4-3HA-RUNX3 plasmids. Levels of HIF-1a, RUNX3 and PHD2 were determined with appropriate antibodies by immunoblotting. Three independent experiments were performed in triplicate. (g) MKN1 cells were transfected with two kinds of small interfering RNAs targeting PHD2 in the presence or absence of RUNX3 plasmid followed by hypoxic exposure for 24 h. VEGF mRNA level was then evaluated by real-time PCR. Cell lysates were immunoprecipitated with anti-HIF-1a antibody and immunoblotted with an anti-PHD2 and RUNX3 antibody. Normoxic control cells were treated with MG132 for 6 h before cells were harvested.
in (Figure 7d ), RUNX3-non-expressing SNU668 cells and hypoxic MKN1 cells significantly induced functional blood vessels in Matrigel. On the other hand, the CMs of normoxic MKN1 cells and hypoxic RUNX3-overexpressing MKN1 cells clearly reduced microvessel formation within Matrigel implants as determined by CD31positive microvessel densities (Figure 7d ). These results indicate that RUNX3 inhibits angiogenic responses under both normoxic and hypoxic conditions. To confirm that HIF-1 inhibition by RUNX3 has a major role in angiogenesis inhibition under hypoxia, we performed tube formation assays. RUNX3-overexpressing CM significantly inhibited hypoxic CM-stimulated tube formation and branching, whereas CM from MG132-treated cells and PHD2 silencing cells recovered the RUNX3-mediated inhibition of tube formation (Figure 7e ). Taken together, these results Chick CAM assays were performed using the CM described in (a). CMs were applied to the CAM surfaces of 4-day-old chick embryos. The graph shows the percentages of eggs positive for new blood vessel among all eggs tested. Significant differences from normoxia (N) and hypoxia (H) were accepted for *P-values of o0.01 and **P-values of o0.01. (d) Matrigel plug assays were performed using the CM described in (a) and CMs from MKN1 and SNU668 cells. Matrigel (500 ml) containing CM (100 ml) was inoculated into a flank of C57BL6/J mice and Matrigel plugs were excised 7 days later. A picture of a Matrigel plug is shown in the left panel. CD31-positive cells were counted after immunostaining cryosections (10 mm) and fixing them with 4% paraformaldehyde. Three independent experiments were performed in triplicate. (e) Twenty-four well dishes were coated with Matrigel and HUVEC tube formation assays were performed over 24 h using the CM described in (a). The upper panel shows the total tube lengths measured, and the lower panel shows the tube structures formed under the indicated conditions. N: normoxia, H: hypoxia, R3: RUNX3 overexpression, MG132: MG132-treatment, PHDsi: PHD2 small interfering RNA transfectants. Significant differences from normoxia (N) were accepted for *P-values of o0.01 and from hypoxia for **P-values of o0.01. (f) Schematic summary of our hypothesis and results.
suggest that RUNX3 inhibited hypoxia-induced angiogenesis and HIF-1a stability via PHD2 recruitment into the HIF-1a ODD domain by interacting with PHD2 and HIF-1a.
DISCUSSION
Here, we report that RUNX3 destabilized HIF-1a a key upstream transcriptional factor of angiogenic molecules, under hypoxic conditions, and that RUNX3 strongly inhibited hypoxia-induced angiogenesis. Furthermore, HIF-1a was found to interact physically with RUNX3 at CTAD and with PHDs in vitro, and RUNX3 decreased the stability of HIF-1a at the post-translational level. In addition, RUNX3 blocked the nuclear expression of HIF-1a and increased its ubiquitination. This was caused by increased hydroxylation of the ODD domain of HIF-1a due to an interaction between HIF-1a and PHD2, which in turn, resulted in the degradation of HIF-1a (Figure 7f ). RUNX3 acts as a tumor suppressor during the developments of various cancers, 10, 11 and inhibits tumors by inhibiting VEGF expression. 15 It has been suggested that RUNX3 acts as a transcriptional repressor of VEGF, based on gel shift assay and VEGF promoter activity results. 15 Because we used the 5 Â HRE sites in VEGF promoter and excluded RUNX3 binding sites, 16 we only determined HIF-mediated gene expression by RUNX3. In solid tumors, VEGF is strongly induced under hypoxic conditions via the induction of HIF-1a, 22 which is stabilized by the incapacitation of molecules that degrade HIF-1a. Furthermore, HIF-1a is hydroxylated by PHDs in the presence of oxygen, and then interacts with ubiquitin E3 ligase (pVHL), which results in HIF-1a ubiquitination and the targeting of HIF-1a by proteasomes for degradation. 23 In general, molecules that destabilize HIF-1a, such as pVHL, 8 function as tumor suppressors. Furthermore, in addition to pVHL, the proteins p53, 24 PTEN 25 and ARD1 26,27 destabilize HIF-1a and inhibit tumor angiogenesis. The present study for the first time demonstrates that RUNX3 act as a tumor suppressor by destabilizing HIF-1a.
PHD2 is a key member of the iron-containing 2-oxoglutaratedependent dioxygenases superfamily in the contexts of HIF regulation and vessel development. 28 Even the activities of PHDs are decreased in hypoxia, 29 a loss-of-function study using the lentiviral transduction of shPHDs, showed that at 1% O 2 PHD2 degrades HIF-1a, 30 which suggests that PHD2 activity is preserved under hypoxia. It has been reported that in hypoxic cells, PHD2 activity is present and acts to degrade HIF-1a. Furthermore, although HIF-1a is hydroxylated under mild hypoxic conditions it remains stable. Because PHDs are active under hypoxic conditions, the degree of hydroxylated proline 402 or proline 564 is dependent on O 2 concentration and the duration of hypoxic conditions. Furthermore, the partial hydroxylation of proline 402 or proline 564 can be detected by pVHL E3 ligase to degrade HIF1a. 31, 32 The findings that the expressions of PHD2 and PHD3 are increased under chronically hypoxic conditions for 72 h and that HIF-1a levels are decreased, may explain why HIF-1a is degraded under long-term hypoxia. 32 Therefore, RUNX3 can enhance the degree of hydroxylation of proline 402 and proline 564 (Figure 6a ) by enhancing the interaction between PHD2 and HIF-1a to degrade HIF-1a even under hypoxic conditions (1% O 2 , 24 h) (Figure 6g ). On the basis of our findings, we suggest that interaction between PHD2 and RUNX3 enhances HIF-1a hydroxylation by preserving the enzyme activity of PHD2, or alternatively, that RUNX3 directly enhances the enzymatic activity of PHD2 by an unidentified mechanism.
The targeting of HIF-1a potentially provides an efficient means of inducing cancer regression, inhibiting metastasis and overcoming therapeutic resistance. 33, 34 In the present study, RUNX3 inhibited HIF-1a stability by increasing the ubiquitination of HIF1a ( Figure 4) . It is possible that by direct binding to HIF-1a CTAD (Figure 5c ), RUNX3 potentiates and/or mediates the interaction between PHD2 and HIF-1a and then induces HIF-1a hydroxylation. Increased levels of hydroxylated HIF-1a due to mediation of the interaction between PHD2 and HIF-1a by RUNX3 (Figure 6a ) can be polyubiquitinated and degraded. Furthermore, the involvement of RUNX3 might be crucial for the interaction between PHD2 and HIF-1a.
Peng et al. 16 demonstrated that RUNX3 inhibits VEGF transcription, 18 and in the present study, we found that RUNX3 inhibited the expression of HIF-1a and subsequently HIF-1-mediated VEGF expression. Thus, VEGF downregulation by RUNX3 could be due to direct transcriptional inhibition, or due to indirect inhibition of HIF-1-mediated transcription via the destabilization of HIF-1a. In the present study, RUNX3-silenced cells expressed HIF-1a protein, secreted more VEGF protein into culture media, and had higher HRE promoter luciferase activities than RUNX3-expressing MKN1 cells (Figures 1 and 3) . Furthermore, the recovery of RUNX3 expression under hypoxic conditions by treatment with 5-Aza and/or TSA markedly suppressed the expressions of HIF-1a and VEGF and their secretions (Figure 2b and Figure 3c ). These findings show that HIF-1a expression is inversely related to RUNX3 expression, which suggests that the overexpression or restoration of RUNX3 presents a possible means of inhibiting hypoxia-induced or HIF-1a-mediated angiogenesis or metastasis and of inhibiting cancer progression.
In addition, it was interesting to find that the C-terminal mutant (1-187) of RUNX3 did not decrease HIF-1a levels. This mutant was a dominant-negative form of RUNX3 and included an intact DNA-binding domain (the Runt-domain) but lacked the transactivation domain. Previous studies have reported that RUNX3 (1-187) does not have tumor suppressive effects on gastric cancer cells, 35 but that it is expressed in cytosol, increases xenograft tumor growth 36 and blunts TGF-b-induced cell death in gastric cancer cells, 37 which indicate that RUNX3 (1-187) behaves as an oncogene that increases HIF-1a stability and tumor progression.
Even when RUNX3 is not silenced, its subcellular localization is critical for its inactivation. 38 The phosphorylation of RUNX3 by pim-1 39 or Scr kinases 40 induces its cytoplasmic localization. 39 Furthermore, Jun-activation domain-binding protein 1 increases the cytoplasmic expression and degradation of RUNX3, 41 because sequestration in cytoplasm promotes its proteasome-mediated ubiquitination. However, the acetylation of lysine residues of RUNX3 suppresses its degradation, and HDAC is known to be involved in its inactivation and degradation. Accordingly, increased HDAC expression and activity under hypoxia may diminish the expression and contribute to the mislocalization of RUNX3. 1 HDACs increase HIF-1a stabilization, 42, 43 and thus, HDAC inhibitors recover the function of RUNX3 to inhibit HIF-1a and may, in part, be responsible for its anti-angiogenic effect. 1, 44 In most gastric cancer tissues, the expression of RUNX3 was lost or the protein was aberrantly localized to the cytoplasm. 12, 45 On the other hand, HIF-1a expression in gastric cancer tissues has been reported to be elevated. 46 Therefore, we suggest that relations between the expressions of HIF-1a and RUNX3 in gastric cancer tissues and clinicopathological variables are probably difficult to prove. In addition, cancer tissues bear multiple genetic and epigenetic alterations, and thus, are not necessarily represented by results obtained in defined experimental systems.
In conclusion, the results of the present study lead us to conclude that small molecules or molecular strategies that cause the re-expression or induce the overexpression of RUNX3 might inhibit HIF-1a expression during cancer angiogenesis and metastasis. [2] [3] [4] [5] were grown on 1% gelatin-coated culture plates in M199 (Gibco, Rockville, MD, USA) supplemented with 20% fetal bovine serum, 1 Â antibiotics (100 units/ml penicillin, 100 mg/ml streptomycin, Invitrogen, Carlsbad, CA, USA), bFGF (2 ng/ml) and heparin (5 unit/ ml, Sigma, St Louis, MO, USA). Subconfluent HEK293 cells were transiently transfected with pCS4-3myc-RUNX3 (full-length) or pGL3-5 Â HRE-VEGFLuc expression plasmids 15 using Vivamagic Transfection Reagent (Vivagene, Seongnam, Korea), according to the manufacturer's instructions.
MATERIALS AND METHODS

Luciferase assay
After transfection, cells were harvested and lysates were prepared using reporter lysis buffer (Promega, Madison, WI, USA). Lysates were analyzed for luciferase activity using an assay kit (Promega, Madison, WI, USA) and a luminometer (Turner Designs, Sunnyvale, CA, USA). Extracts were assayed three times using a b-galactosidase enzyme assay kit (Promega, Madison, WI, USA). Relative luciferase activities were calculated as relative luciferase units with respect to b-galactosidase.
Enzyme-linked immunosorbent assay for VEGF
The levels of VEGF protein secreted by MKN1 and SUN668 cells were determined using the Quantikine human VEGF ELISA kit from R&D Systems (Minneapolis, MN, USA). Cells were plated in six-well plates and cultured until 80-90% confluent. Secreted VEGF in extracellular medium was quantified, according to the manufacturer's instructions. Results were normalized versus total protein levels. A serial dilution of human recombinant VEGF was included in each assay to obtain a standard curve.
Tube formation assay
Human umbilical vein endothelial cells were seeded on 35-mm dishes coated with Matrigel (10 mg/ml, BD Biosciences, San Diego, CA, USA) for 30 min at 37 1C, and then stimulated with CM from mock or RUNX3-transfected cells under normoxic or hypoxic conditions for 24 h. Morphologic changes were observed under a microscope and photographed at 100 Â .
Chorioallantoic membrane assay
Amniotic membranes and albumin were removed at 3.5 days after fertilization, and at 9.5 days, air-dried CM from mock or RUNX3-transfected cells cultured under normoxic or hypoxic conditions on Thermanox (Nunc, Rochester, NY, USA) was loaded onto chick chorioallantoic membrane surfaces. Two days later, a 10% fat emulsion was injected into the chorioallantois and chorioallantoic membrane surfaces were observed under a microscope at 50 Â (Stemi 2000C, Zeiss, Gö ttingen, Germany). The responses were scored as positive vascular sprouting and percentages of positive eggs among eggs tested were calculated. Fifteen eggs per group were used in each of the three independent experiments.
In vivo Matrigel assay in mice and immunohistochemistry
CMs from MKN1 cells transfected with RUNX3 full-length or mock plasmid under hypoxic or normoxic conditions were mixed with 300 ml Matrigel (BD Biosciences) and inoculated subcutaneously into both flanks of C57Bl/6J mice. Matrigel plugs were removed at 7 days after inoculation and photographed. Matrigel plugs submitted for immunohistochemistry were also fixed with 4% paraformaldehyde (pH 7.4). Serial sections (5 mm) were mounted on poly-L-lysine coated slides, and processed for histology or immunohistochemistry. Sections were immunostained with antibodies against mouse CD31 (BD Biosciences), visualized using appropriate biotinconjugated secondary antibodies and treated with a Vectastain ABC Elite kit and diamino-benzidine (DAB) substrate (Linaris, Wertheim, Germany). Counterstaining was performed with hematoxylin and sections were photographed under a light microscope at 200 Â (Zeiss, Gö ttingen, Germany).
Statistical analysis
Analysis of variance was used to determine the significances of differences between the experimental groups. Statistical significance was accepted for P-values of o0.01 or Po0.05, as indicated. Results are presented as means±s.d.
